The clinical course of intrinsic supratentorial tumours is variable. Prediction of outcome would be useful in defining patients for specific treatment policies. A retrospective analysis of 560 patients with intrinsic supratentorial tumours was performed. Proportional hazards models for survival were derived by using a stepwise selection procedure with only clinical and CT features as possible explanatory variables. The variables of prognostic importance were age, a first symptom of epilepsy, focal signs at presentation, a cystic lesion on CT scan, and duration of symptoms before presentation. The model defined a group with a good prognosis (score < 9, n = 211) and a group with a poor prognosis (score > 9, n = 344). The median survival was 27 months for those with a score < 9 or less and three months for those with score > 9. 
Abstract
The clinical course of intrinsic supratentorial tumours is variable. Prediction of outcome would be useful in defining patients for specific treatment policies. A retrospective analysis of 560 patients with intrinsic supratentorial tumours was performed. Proportional hazards models for survival were derived by using a stepwise selection procedure with only clinical and CT features as possible explanatory variables. The variables of prognostic importance were age, a first symptom of epilepsy, focal signs at presentation, a cystic lesion on CT scan, and duration of symptoms before presentation. The model defined a group with a good prognosis (score < 9, n = 211) and a group with a poor prognosis (score > 9, n = 344). The median survival was 27 months for those with a score < 9 or less and three months for those with score > 9. An alternative model, not including duration of symptoms, is also capable of defining groups with long (score < 16, n = 234) and short (score > 1  70  24  34  99  108  92  74  2  81  57  3  15  66  53  46  3  63  52  3  9  41  45  29  4  71  61  2  6  15  30  17  5  51  49  2  6  11  21  11  6  81  79  1  3  7  10  2  7  142  142  1 variable from which the relative risk of mortality, associated with that variable, may be calculated. Once the model has been selected, continuous variables were categorised and a score indicating the prognosis was derived from the coefficients of the signs and symptoms. The beta coefficient for each variable is rounded off to the nearest decimal place and then multiplied by ten to give a variable score. The total prognostic score for each individual is the sum of the variable scores. Each patient is assigned to a prognostic group defined by their total score. The survival rates of prognostic groups defined by using this-score were then determined. Cross-validation was used to assess the extent to which this score is dependent on a specific data set. The data were split into two subsets by using random numbers, three such partitions of the data being created. Statistical models were developed, by the stepwise procedure, for each of the subsets. This enables comparison of the relative prognostic importance of different variables. The more often a variable is selected for different partitions the more confident one can be about the prognostic significance of that variable. Furthermore, such a variable would probably be of predictive value in a new group of patients. Scores were derived for both subsets of each partition and the score for one subset was used to divide the complementary subset into prognostic groups predicted to have good, fair, or poor survival. To assess the validity of these predictions the actual survival rate of these groups was found. The influence of the five patients with survival longer than 10 years was assessed by repeating the above procedure with these patients excluded.
Results
The selected explanatory variables and their Table 4 Number of patients at risk after diagnosis according to prognostic index 0  215  344  234  325  10  130  48  165  13  20  96  21  114  3  40  72  8  79  1  80  17  3  18  0  120  3  1  4  0   272 group.bmj.com on December 30, 2017 -Published by http://jnnp.bmj.com/ Downloaded from Development ofprognostic index for primary supratentorial intracerebral tumours coefficients in decreasing order of importance from the full data set were age, first symptom of epilepsy, focal signs at presentation, a cystic lesion on CT, and the duration of symptoms before presentation (table 1) . To distinguish further which factors discriminate between groups the five patients with long survival (> 10 years) were excluded and subsequent analysis indicated that enhancing and low density lesions on CT and mental symptoms at presentation may also be included as explanatory variables. A prognostic index was derived from these variables by categorising the patients as young (< 45 years), middle aged (45-59 years), and old (> 59 years) and the duration of symptoms as negligible (a few days or less), short (up to two months), and prolonged (longer than two months). Scores were assigned to reflect the coefficients in the hazard function, and the total score (arithmetic sum) was used to define seven groups of patients with increasingly poor prognosis (table  2) . The survival experience of these groups does decline (table 3) with the first group having a median survival of more than eight years and the seventh group a median survival of two months. Figure 1 shows the clearly different survival experience of patients divided into two groups according to prog-80 100 120
Months after diagnosis Eight variables were selected as predictors of survival for at least one random subset. The combinations in which they occur are shown in table 5. Between three and six variables may be selected. Age was always selected with a coefficient varying from 0-024 to 0-040 and a hazard ratio of 1-74 to 2-51 per decade. Whether or not the first symptom was epilepsy is consistently important with hazard ratios for those presenting with epilepsy ranging from 0-05 to 0 30 in these partitions. Focal signs at presentation was also consistently identified as an adverse prognostic factor with hazard ratios of 2-47 to 4-53. Cystic, enhancing, and low density lesions on CT may be combined with mental signs at presentation to replace duration of symptoms in predicting outcome (table 5) .
A further method of validation was used in which the whole data set was divided into two subsets. Scores derived from each of these subsets are given in table 6 and used to define three prognostic groups: good, fair, and poor. The accuracy of the scores was then tested in the other subset (table 7) . Scores on one subset of data may be used to predict which patients from the other subset are likely to have a fairly long life and those who will die within a few months. Age, the first symptom, and focal signs at presentation remain important when those with long survival are excluded (table 8) . Additional variables were selected into the explanatory models for some of the subsets of the partitions. Again these appear to be variables which are indicators of the duration of symptoms. An alternative score, which does not include duration of symptoms, is therefore presented in table 9. Using a total score of < 16 to define a good prognosis gives two groups with very different survival experience (figure 2). The number of patients in each group who are at risk at different durations of follow up is shown in table 4 come through the regional departiment for diagnosis and initial management. Such patients presented to both neurologists and neurosurgeons, with a wide spectrum of presenting symptoms and signs, and both conservative and aggressive management policies were used. While one neurosurgeon did not contribute this is otherwise a fairly complete sample. A few clinical and radiological variables were found to be important in predicting outcome. Using cross-validation procedures the factors which were consistently selected as being of prognostic importance were age at presentation, presentation with epilepsy, and focal neurological deficit. Our present models could be criticised because they take no account of potential treatment effects in influencing outcome. The main purpose of the model is, of course, the identification at diagnosis of patients with different prognoses. The potential treatment effects influencing outcome have been examined in another publication.2 Patients with epilepsy and therefore a good outcome were as likely to receive resective surgery or radiotherapy as those with other modes of presentation associated with a poorer outcome. Radiotherapy did improve survival in the complete data set but not in those presenting with epilepsy. There is a suggestion that at least some of the apparent effects of radiotherapy in our patients could have been due to selection of patients with better prognoses for this treatment.7 While prospective validation of our models will need to take into account treatment effects, the evidence above would suggest that pretreatment predictors derived from our data set are accurate in defining prognosis.
Patients with good, intermediate, and poor prognoses may be differentiated by using a score derived from a proportional hazards Table 8 Frequency with which variables are selected using three randomly generated partitions of the data set (survival < 120 months) 
